• Explore /
  • Poster
  • / Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

Immunoscore to provide prognostic information in low- (T1-3N1) and high-risk (T4 or N2) subsets of stage III colon carcinoma patients treated with adjuvant FOLFOX in a phase III trial (NCCTG N0147; Alliance).

Abstract Poster

Authors

null

Frank A. Sinicrope

Mayo Clinic, Rochester, MN

Frank A. Sinicrope , Qian Shi , Fabienne Hermitte , Erica N Heying , Al Bowen Benson III, Sharlene Gill , Richard Goldberg , Morton S. Kahlenberg , Suresh Nair , Anthony Frank Shields , Daniel J. Sargent , Jerome Galon , Steven R. Alberts

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 Gastrointestinal Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session C: Cancers of the Colon, Rectum, and Anus

Track

Cancers of the Colon, Rectum, and Anus

Sub Track

Translational Research

Citation

J Clin Oncol 36, 2018 (suppl 4S; abstr 614)

DOI

10.1200/JCO.2018.36.4_suppl.614

Abstract #

614

Poster Bd #

C19

Abstract Disclosures

Similar Posters

First Author: Rona Yaeger

First Author: Masahito Kotaka

First Author: Jean Francois Delattre

First Author: Takuya Miura